A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Gilead Sciences
St. Jude Children's Research Hospital
Allogene Therapeutics
Allogene Therapeutics
Allogene Therapeutics
Lyell Immunopharma, Inc.
M.D. Anderson Cancer Center
Senti Biosciences
Gilead Sciences
Baylor College of Medicine
Celgene
Therapeutic Advances in Childhood Leukemia Consortium
University of Pennsylvania
Gilead Sciences
Chinese PLA General Hospital
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of Maryland, Baltimore
Affiliated Hospital to Academy of Military Medical Sciences
Affimed GmbH
Dana-Farber Cancer Institute
Chinese PLA General Hospital
University Health Network, Toronto
University of Pennsylvania
University of Illinois at Chicago
CARGO Therapeutics